Evotec Faces Shareholder Reshuffle Amid Major Restructuring

Evotec SE announces deep job cuts and site consolidation, triggering a major stock drop and anchor investor exit. A new investor emerges as the company prepares to release pivotal 2025 results on April 8th.

A significant shift is underway in the shareholder base of Evotec SE, coinciding with the most extensive operational overhaul the company has ever undertaken. These converging developments set the stage for April 8th to become a pivotal date for investors.

Deep Cuts and Market Reaction

The current fluidity in ownership structure stems directly from a strategic shock. On March 10, 2026, Evotec unveiled its "Horizon" transformation plan. This sweeping initiative involves cutting up to 800 jobs, consolidating operations to 10 global sites, and targeting annual savings of €75 million by 2027. The market's verdict was severe: the stock plummeted 22.71% in a single trading week, marking one of the steepest declines in the TecDAX index.

The financial data underpinning this move reveals the pressure to act. Preliminary 2025 figures show a company running on two tracks. The biologics subsidiary, Just – Evotec Biologics, grew revenue by approximately 40% to around €259 million, contributing a positive EBITDA of about €53 million. In stark contrast, the traditional Discovery segment contracted by 13% to roughly €529 million, posting a negative EBITDA of circa €12 million.

Anchor Investor Exits as New Player Emerges

In this turbulent context, the shareholder register is seeing notable changes. In December 2025, long-term anchor investor Novo Holdings divested its entire stake. Approximately 9.4 million shares changed hands at a price of around €5.10 per share. This exit removes Evotec's second-largest shareholder, which initially entered via a capital increase in 2017.

The consequence is a rise in the free float to about 83%. While this enhances trading liquidity, it also potentially increases the stock's susceptibility to price volatility. Remaining anchor shareholders with stakes exceeding 5% each are Triton GP HoldCo SARL and Mubadala Investment Company.

Almost simultaneously, a new institutional name appeared. MAK Capital Fund LP (Michael Kaufman) reported direct voting rights of 5.01% as of January 9, 2026. This new position at the current price level signals interest, though the long-term commitment remains to be seen.

The Proof Point on the Horizon

All eyes are now on the upcoming report. On April 8th, Evotec will release its final audited results for the full year 2025. Market participants will scrutinize this release for the earliest indicators regarding the execution of the Horizon plan. The company itself has cautioned that operational benefits from the restructuring are not anticipated until the second half of 2026.

Guidance for the current year underscores the near-term pain. For 2026, Evotec forecasts revenue between €700 million and €780 million, with an adjusted EBITDA ranging from just €0 to €40 million. This falls significantly below analyst expectations, which had been for over €80 million, as implementation costs weigh heavily on the current year's results.

The long-term ambition, however, aims for an adjusted EBITDA margin of 20% by 2028. This target leans heavily on the higher-margin biologics business, which recently secured a new grant from the Gates Foundation. Until tangible progress emerges, the equity, which has lost roughly 23% since the start of the year, remains under pressure to demonstrate that its transformative horizon is within reach.